Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 16/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10208244 | 0.81 | HDAC6 (0.40) | SMYD3HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL7918355 | 0.77 | NR3C2 (0.51) | SMYD3HDAC8 | |
| SCHEMBL26050914 | 0.74 | HDAC1 (0.56) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL722899 | 0.74 | HDAC6 (0.43) | SMYD3HDAC6HDAC1HDAC3HDAC2 | |
| SCHEMBL10207564 | 0.73 | HDAC6 (0.46) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL10224031 | 0.71 | HDAC6 (0.47) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL10224354 | 0.71 | HDAC6 (0.55) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL10224223 | 0.71 | HDAC6 (0.44) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL10208232 | 0.71 | HSD11B1 (0.51) | HDAC6HDAC1HDAC3HDAC2HDAC8 | |
| SCHEMBL25346090 | 0.71 | HDAC6 (0.43) | SMYD3HDAC6HDAC1HDAC3HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8471026-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | claimed |
| US-9249142-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20150105418-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2015-04-16 | — | — | US | disclosed |
| US-8952163-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-20140142108-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2014-05-22 | — | — | US | disclosed |
| US-8471026-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120053201-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053201-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | SMYD3 2190/4885HDAC6 1/4885HDAC1 2/4885 |
| US-20140142108-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | SMYD3 2190/4885HDAC6 1/4885HDAC1 2/4885 |
| US-20150105418-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC2 | SMYD3 2190/4885HDAC6 1/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.